Genitourinary Cancer

Top Story

FDA grants priority review to MCNA for nonmuscle-invasive bladder cancer

August 31, 2015

The FDA granted priority review to MCNA for patients with high-risk nonmuscle-invasive bladder cancer, according to a press release from the drug’s manufacturer.

MCNA (mycobacterium phlei cell wall-nucleic acid complex, Telesta Therapeutics) — a biologic therapy derived from the cell wall fractionation of non-pathogenic bacteria —  is intended for patients with bladder cancer who are refractory to or who relapsed on front-line therapy with a therapeutic alternative to surgery.

FDA News

FDA grants breakthrough drug designation to cabozantinib for advanced renal cell carcinoma

August 24, 2015
The FDA granted breakthrough drug designation to cabozantinib for the treatment of patients with renal cell carcinoma who received one prior therapy, according to a…
In the Journals

Genomic alterations predict chemotherapy response in muscle-invasive bladder cancer

August 14, 2015
Genomic alterations in certain DNA repair-associated genes predicted response to and clinical benefit from neoadjuvant cisplatin chemotherapy for muscle-invasive bladder…
In the Journals

Weight cycling does not increase cancer risk

August 10, 2015
Weight cycling does not appear associated with elevated cancer risk, according to an analysis of data from a large prospective cohort.Nearly half of all U.S. adults have…
CME
Updates in Immunotherapy – Philadelphia 2015

Updates in Immunotherapy – Philadelphia 2015

This activity is supported by an educational grant from Merck & Co., Inc.

The promise of immunotherapy in oncology has become a reality with the US Food and Drug Administration (FDA) approval…
More »
Meeting News Coverage Video
Recurrent themes of ASCO: Money and molecules

Recurrent themes of ASCO: Money and molecules

June 7, 2013
CHICAGO — Donald L. Trump, MD, FACP, president and CEO of Roswell Park Cancer Institute, offers his insights on…
More »
CME
Hematology Oncology Case Consults

The Patient with Multiple Myeloma

No commercial support for this activity.

This CME activity will focus on the diagnosis and management of patients with multiple myeloma.
More »
FDA News

FDA grants priority review to MCNA for nonmuscle-invasive bladder cancer

August 31, 2015
The FDA granted priority review to MCNA for patients with high-risk nonmuscle-invasive bladder cancer, according to a press release from the…
FDA News

FDA grants breakthrough drug designation to cabozantinib for advanced renal cell carcinoma

August 24, 2015
The FDA granted breakthrough drug designation to cabozantinib for the treatment of patients with renal cell carcinoma who received one prior therapy…
In the Journals

Genomic alterations predict chemotherapy response in muscle-invasive bladder cancer

August 14, 2015
Genomic alterations in certain DNA repair-associated genes predicted response to and clinical benefit from neoadjuvant cisplatin chemotherapy for…
In the Journals

Weight cycling does not increase cancer risk

August 10, 2015
Weight cycling does not appear associated with elevated cancer risk, according to an analysis of data from a large prospective cohort.Nearly half of…
Preet Paul Singh, MBBS Cover StoryPerspectivePublication Exclusive

Clinical trials, ‘a lot more study’ needed to confirm statins’ effects on cancer outcomes

HemOnc Today, August 10, 2015
For millions of Americans, taking a statin represents an integral part of everyday life.Twenty-six percent of Americans regularly use a…
Charis Eng, MD, PhD CommentaryPublication Exclusive

Abstracts highlight importance of identifying, managing germline mutations in patients with somatic genomic testing of cancer

HemOnc Today, August 10, 2015
Charis Eng, MD, PhD
A series of at least five unrelated abstracts presented at this year’s ASCO Annual Meeting — including the one by Hall and colleagues…
Nancy N. Baxter, MD, PhD In the Journals

Survivors of young adult cancers face increased hospitalization risk into adulthood

August 5, 2015
Survivors of young adult cancers experienced elevated rates of hospitalization compared with cancer-free controls, according to study…
Charis Eng, MD, PhD In the Journals

Risk calculator an accurate, cost-effective prescreening tool for PTEN mutations

July 30, 2015
The PTEN Cleveland Clinic score appeared to be a cost-effective prescreening tool to identify patients with Cowden-like disease who are appropriate…
FDA News

FDA grants breakthrough drug designation to Lenvima for advanced RCC

July 29, 2015
The FDA granted breakthrough drug designation to lenvatinib for the treatment of patients with advanced or metastatic renal cell carcinoma who…
FDA News

FDA grants breakthrough therapy designation to Azedra for pheochromocytoma, paraganglioma

July 28, 2015
The FDA granted breakthrough therapy designation to Ultratrace iobenguane I-131 for the treatment of patients with iobenguane-avid metastatic or…
More Headlines »
morganatic-roan